Editor’s Note: This article originally appeared on ECG’s website.
The exponential growth of emerging medical technologies will likely accelerate over the next few years, particularly in the cardiovascular (CV) service line and, more specifically, within mitral valve (MV) treatments. Transcatheter aortic valve repair (TAVR) recently paved the way for valve-specific CV programs by demonstrating that these business models can succeed in focusing on a specific category of the heart. Additionally, TAVR proved that patients are willing to travel for well-established programs that demonstrate their ability to provide innovative care. Combined with this subspecialization trend is a wave of MV-specific technologies and devices that will likely go to market in the coming years. This combination of factors presents a new opportunity for forward-looking CV service lines.
Untreated Population
As it stands today, MitraClip is the leading solution used in MV surgery, but it does not serve many variations of MV disease, leaving numerous patients without a viable treatment option. For example, mitral regurgitation (MR), a common variant of MV disease, allows blood to leak backward into the left atrium of the heart and, if not treated, can result in heart muscle damage. Click here to continue>>
News from Our Partner
